Unknown

Dataset Information

0

Maintenance of antibody response to diphtheria/tetanus vaccine in patients aged 2-5?years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept.


ABSTRACT: BACKGROUND:Patients with polyarticular-course juvenile idiopathic arthritis (pJIA), receiving disease-modifying anti-rheumatic drugs with immunosuppressive effects, may be at increased risk of vaccine-preventable infections. This substudy assessed protective antibody responses to diphtheria and tetanus vaccination given prior to study enrolment in patients with pJIA. FINDINGS:This was a substudy of a 24-month, single-arm, open-label, multicenter, Phase III trial (NCT01844518) of subcutaneous abatacept in children with active pJIA (N =?219). Patients aged 2-5?years, with ?2 continuous months of weekly weight-tiered (10-?0.1?IU/mL), and safety, were assessed. Overall, 29 patients were analyzed: 19 (65.5%), 1 (3.4%) and 9 (31.0%) patients had >?12, 6-12 and 2-

SUBMITTER: Brunner HI 

PROVIDER: S-EPMC7036185 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Maintenance of antibody response to diphtheria/tetanus vaccine in patients aged 2-5 years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept.

Brunner Hermine I HI   Tzaribachev Nikolay N   Cornejo Gabriel Vega GV   Joos Rik R   Gervais Elisabeth E   Cimaz Rolando R   Calvo Penadés Inmaculada I   Cuttica Rubén R   Lutz Thomas T   Quartier Pierre P   Gandhi Yash Y   Nys Marleen M   Wong Robert R   Martini Alberto A   Lovell Daniel J DJ   Ruperto Nicolino N  

Pediatric rheumatology online journal 20200222 1


<h4>Background</h4>Patients with polyarticular-course juvenile idiopathic arthritis (pJIA), receiving disease-modifying anti-rheumatic drugs with immunosuppressive effects, may be at increased risk of vaccine-preventable infections. This substudy assessed protective antibody responses to diphtheria and tetanus vaccination given prior to study enrolment in patients with pJIA.<h4>Findings</h4>This was a substudy of a 24-month, single-arm, open-label, multicenter, Phase III trial (NCT01844518) of s  ...[more]

Similar Datasets

| S-EPMC6032847 | biostudies-literature
| S-EPMC8048692 | biostudies-literature
| S-EPMC6492394 | biostudies-literature
| S-EPMC5754736 | biostudies-literature
| S-EPMC8487273 | biostudies-literature
2009-04-13 | GSE15645 | GEO
| S-EPMC7425194 | biostudies-literature
| S-EPMC4216020 | biostudies-other
| S-EPMC11371380 | biostudies-literature
| S-EPMC2727897 | biostudies-other